In the present observational cohort study in 4902 men and 9804 women, we found that the factors associated with osteoporosis care utilization in men were comorbidities, adjuvant hormonal therapy for prostate cancer, vertebral or hip fractures, and glucocorticoid treatment. INTRODUCTION: Male osteoporosis is associated with an important clinical and economic burden worldwide; nevertheless, undertreatment of men with osteoporosis is common. Understanding the factors associated with referral to bone specialists may help to define future interventions to improve access to osteoporosis care for male patients. METHODS: We conducted a retrospective analysis of a nationwide cohort (DeFRACalc79 database). DeFRACalc79 is a tool that estimates the fracture risk by considering clinical and densitometric risk factors, including the presence of prior hip or vertebral and non-vertebral or non-hip fractures. We compared the clinical characteristics of male individuals with an age-matched cohort of women. Propensity score generation with a 2:1 female-to-male ratio was performed using a logistic regression model to age-match the cohorts. RESULTS: We analyzed a sample of 4902 men at high risk for osteoporosis. We found that the factors associated with osteoporosis care utilization in men were the presence of comorbidities (OR 1.939, 95% CI 1.799-2.090), adjuvant hormonal therapy for prostate cancer (OR 1.482, 95% CI 1.315-1.670), the presence of vertebral or hip fractures (OR 1.490, 95% CI 1.378-1.611), and glucocorticoid treatment (OR 2.573, 95% CI 2.274-2.832). CONCLUSIONS: Men are more commonly referred to the bone specialist with a prevalent fragility fracture and/or diagnosis of secondary osteoporosis as compared with women. Our study suggests that there is a lack of screening for the primary prevention of osteoporosis in men as compared with that in women.
In the present observational cohort study in 4902 men and 9804 women, we found that the factors associated with osteoporosis care utilization in men were comorbidities, adjuvant hormonal therapy for prostate cancer, vertebral or hip fractures, and glucocorticoid treatment. INTRODUCTION: Male osteoporosis is associated with an important clinical and economic burden worldwide; nevertheless, undertreatment of men with osteoporosis is common. Understanding the factors associated with referral to bone specialists may help to define future interventions to improve access to osteoporosis care for male patients. METHODS: We conducted a retrospective analysis of a nationwide cohort (DeFRACalc79 database). DeFRACalc79 is a tool that estimates the fracture risk by considering clinical and densitometric risk factors, including the presence of prior hip or vertebral and non-vertebral or non-hip fractures. We compared the clinical characteristics of male individuals with an age-matched cohort of women. Propensity score generation with a 2:1 female-to-male ratio was performed using a logistic regression model to age-match the cohorts. RESULTS: We analyzed a sample of 4902 men at high risk for osteoporosis. We found that the factors associated with osteoporosis care utilization in men were the presence of comorbidities (OR 1.939, 95% CI 1.799-2.090), adjuvant hormonal therapy for prostate cancer (OR 1.482, 95% CI 1.315-1.670), the presence of vertebral or hip fractures (OR 1.490, 95% CI 1.378-1.611), and glucocorticoid treatment (OR 2.573, 95% CI 2.274-2.832). CONCLUSIONS: Men are more commonly referred to the bone specialist with a prevalent fragility fracture and/or diagnosis of secondary osteoporosis as compared with women. Our study suggests that there is a lack of screening for the primary prevention of osteoporosis in men as compared with that in women.
Entities:
Keywords:
Bone mineral density (BMD); Fractures; Male osteoporosis; Men; Risk factors
Authors: Russel Burge; Bess Dawson-Hughes; Daniel H Solomon; John B Wong; Alison King; Anna Tosteson Journal: J Bone Miner Res Date: 2007-03 Impact factor: 6.741
Authors: R B Hopkins; E Pullenayegum; R Goeree; J D Adachi; A Papaioannou; W D Leslie; J E Tarride; L Thabane Journal: Osteoporos Int Date: 2011-05-11 Impact factor: 4.507
Authors: Nguyen D Nguyen; Henrik G Ahlborg; Jacqueline R Center; John A Eisman; Tuan V Nguyen Journal: J Bone Miner Res Date: 2007-06 Impact factor: 6.741
Authors: Radhika Rao Narla; Lianne A Hirano; Serena H Y Lo; Bradley D Anawalt; Elizabeth A Phelan; Alvin M Matsumoto Journal: J Investig Med Date: 2019-02-05 Impact factor: 2.895
Authors: Gary M Kiebzak; Garth A Beinart; Karen Perser; Catherine G Ambrose; Sherwin J Siff; Michael H Heggeness Journal: Arch Intern Med Date: 2002-10-28
Authors: Maria Maddalena Sirufo; Francesca De Pietro; Alessandra Catalogna; Lia Ginaldi; Massimo De Martinis Journal: Int J Environ Res Public Health Date: 2021-12-28 Impact factor: 3.390
Authors: Caitlin McArthur; Ahreum Lee; Hajar Abu Alrob; Jonathan D Adachi; Lora Giangregorio; Lauren E Griffith; Suzanne Morin; Lehana Thabane; George Ioannidis; Justin Lee; William D Leslie; Alexandra Papaioannou Journal: Arch Osteoporos Date: 2022-02-04 Impact factor: 2.617
Authors: Giovanni Adami; Marco Pontalti; Giorgio Cattani; Maurizio Rossini; Ombretta Viapiana; Giovanni Orsolini; Camilla Benini; Eugenia Bertoldo; Elena Fracassi; Davide Gatti; Angelo Fassio Journal: RMD Open Date: 2022-02
Authors: G Adami; G Cattani; M Rossini; O Viapiana; P Olivi; G Orsolini; E Bertoldo; E Fracassi; D Gatti; A Fassio Journal: Osteoporos Int Date: 2021-07-15 Impact factor: 4.507